17:30 , Jan 11, 2019 |  BC Week In Review  |  Company News

Daiichi to market Esperion's LDL-C lowering products in Europe

Esperion Therapeutics Inc. (NASDAQ:ESPR) will get $150 million cash up front in exchange for granting the European subsidiary of Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive rights to commercialize bempedoic acid (ETC-1002) and bempedoic acid/ezetimibe in...
20:03 , Jan 4, 2019 |  BC Extra  |  Company News

Daiichi to market Esperion's LDL-C lowering products in Europe

Esperion Therapeutics Inc. (NASDAQ:ESPR) will get $150 million cash up front in exchange for granting the European subsidiary of Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive rights to commercialize bempedoic acid (ETC-1002) and bempedoic acid/ezetimibe in...
03:14 , Dec 8, 2018 |  BioCentury  |  Regulation

Path to opioid-free pain relief

To jump-start development of analgesics that can help stem the opioid crisis, companies want FDA’s upcoming guidelines to reduce uncertainty around outcomes that constitute clinically meaningful opioid sparing. But while an advisory panel put some...
13:10 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting Hsp70 could help treat prostate cancer resistant to Xtandi enzalutamide and/or Zytiga abiraterone acetate. In human prostate cancer cell lines, high Hsp70 levels were associated...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
19:56 , Nov 2, 2018 |  BC Week In Review  |  Company News

J&J appeals district court decision invalidating Zytiga patent

Johnson & Johnson (NYSE:JNJ) on Oct. 31 filed to appeal a district court decision that will permit generic versions of prostate cancer drug Zytiga abiraterone acetate to launch after Oct. 31, according to company spokesperson...
19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Esperion hypercholesterolemia candidate meets in fifth and final Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) as monotherapy met the primary endpoint of reducing LDL-C in the Phase III CLEAR Wisdom (1002-047) trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients...
23:17 , Oct 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
19:44 , Sep 14, 2018 |  BioCentury  |  Emerging Company Profile

Laekna’s jumping off place

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other...
22:07 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...